[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review.

Data de publicació: 13/01/2024 Data Ahead of Print: 13/01/2024

Autors de IIS La Fe

• Miguel Mansilla Polo

  Autor

• Esther Gimeno Genoves

  Autor

Autors aliens a IIS La Fe

• Morgado-Carrasco D

Abstract

Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the treatment of plaque psoriasis and mild to moderate seborrheic dermatitis. Several studies have described the off-label use of roflumilast in dermatology, including a randomized controlled trial showing its usefulness in the treatment of psoriasis; case reports and small series have also reported successful outcomes in hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet disease. Roflumilast has a favorable safety profile, similar to that of apremilast, and it is considerably cheaper than new generation drugs and even some conventional immunosuppressants. We review the pharmacokinetics and pharmacodynamics of topical and oral roflumilast and discuss potential adverse effects and both approved and off-label uses in dermatology. Roflumilast is a promising agent to consider.

Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Keywords

• Apremilast; Dermatology; Dermatología; Fosfodiesterasa; Off-label; Phosphodiesterase; Psoriasis; Roflumilast